Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HEALTHCARE (NY:XLV)

142.56 +0.22 (+0.15%)
Official Closing Price Updated: 8:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
39 40 Next >
Financials, Health Care Sectors Leading US Stocks Higher In 2025
Genius remains a bull market so far in 2025. All the main sectors in the US equities market are posting year-to-date gains, led by financials and health care, based on a set of ETFs. 
Via Talk Markets
Topics ETFs
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page
The analyst sees 2025 as a challenging year due to Eylea headwinds but expects growth to accelerate in 2026, driven by strong eczema treatment sales from the company’s Dupixent drug. 
Via Stocktwits
Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip
The company announced plans to generate $2 billion in annual cost savings by the end of 2027. 
Via Stocktwits
Leading And Lagging Sectors For February 6, 2025
 
Via Benzinga
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat
Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments. 
Via Stocktwits
Communications Have More To Say
Last week was certainly memorable, and it looks like this week is off to a similar start. 
Via Talk Markets
Topics Stocks / Equities
Leading And Lagging Sectors For February 5, 2025
 
Via Benzinga
Merck Retail Traders See Buying Opportunity As Stock Dives Toward Worst Day in 17 Years On Weak Guidance
Gardasil, its HPV vaccine, posted a 17% decline in sales to $1.55 billion, primarily due to lower demand in China. 
Via Stocktwits
Pfizer's Retail Traders Cheer Better-Than-Expected Q4 Even As Stock Dips: ‘Another Beat And Still Crazy Cheap'
Under its restructuring program, Pfizer said it remains on track to deliver $4.5 billion in cost savings by the end of 2025. 
Via Stocktwits
Leading And Lagging Sectors For February 4, 2025
 
Via Benzinga
Can Biotech Stocks Survive The Precarious Macro?
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
Leading And Lagging Sectors For February 3, 2025
 
Via Benzinga
Trump's 25% Tariffs Could Slaughter Canada, Mexico Economies, Hit US Auto Industry, Analysts Warn
Trade war between US, Canada, and Mexico could cause severe economic damage, raise prices, and disrupt supply chains in key industries. 
Via Benzinga
Topics Government World Trade
AbbVie Stock Nears 3-Month High on Q4 Beat As Immunology Growth Eases Humira Slump: Retail Mood Brightens
The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025. 
Via Stocktwits
Leading And Lagging Sectors For January 31, 2025
 
Via Benzinga
How We Can Trade On GDP
What we got today, of course, was advance GPD, which is the earliest measure and also the most likely to provoke a reaction in stocks. 
Via Talk Markets
Topics Commodities Futures Stocks / Equities
Leading And Lagging Sectors For January 30, 2025
 
Via Benzinga
Leading And Lagging Sectors For January 29, 2025
 
Via Benzinga
Does China AI Threaten US Tech Dominance?
Anxiety about the competitive threat from Chinese artificial intelligence lab DeepSeek triggered a sharp selloff in US equities on Monday, with the worst of the decline centered in tech. 
Via Talk Markets
Topics Artificial Intelligence ETFs
Leading And Lagging Sectors For January 28, 2025
 
Via Benzinga
Biotech And Healthcare Stocks Poised For Gains Ahead
The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech. 
Via Talk Markets
Topics ETFs Stocks / Equities
Leading And Lagging Sectors For January 27, 2025
 
Via Benzinga
Moderna Retains Retail Support With European COVID-19 Vaccine Tender Win, Stock Hits 2-Week High
The agreement, which spans up to four years, allows 17 participating countries access to Moderna’s vaccine in various formats. 
Via Stocktwits
Leading And Lagging Sectors For January 24, 2025
 
Via Benzinga
Elevance Health Stock Rises On Upbeat Q4 Revenue, Dividend Boost: Retail's Over The Moon
The firm’s medical-loss ratio (MLR) rose to 92.4% due to Medicaid-related costs but was better than expected. 
Via Stocktwits
Leading And Lagging Sectors For January 23, 2025
 
Via Benzinga
J&J Stock Dips As 2025 Sales Guidance Misses Estimate, But Retail Mood Resilient
During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually. 
Via Stocktwits
Topics Earnings
Leading And Lagging Sectors For January 22, 2025
 
Via Benzinga
Small Caps Soar, Apple Slips, Treasury Yields Fall On Trump Day 2: What's Driving Markets Tuesday?
Wall Street saw a strong preference for small and mid-cap equities, with the Russell 2000 index leading the market as investors bet on more domestic-friendly policies following Donald Trump's... 
Via Benzinga
Topics Government
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump
In 2023, Moderna initiated a Phase 1/2 study to assess the safety and immunogenicity of its investigational bird flu vaccine, mRNA-1018, in healthy adults aged 18 and older. 
Via Stocktwits
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.